IP Library Granted Patent US 8,753,622
Granted Patent B2
US 8,753,622 · App. 13/209,124 · Granted Jun 17, 2014

Seneca valley virus based compositions and methods for treating disease

Inventors: Paul Hallenbeck (Chester Springs, PA); Seshidhar Reddy Police (Chester Springs, PA); Laura M. Hales (Chester Springs, PA); Carl Hay (Damascus, MD); Shanthi Ganesh (San Francisco, CA); Ling Xu (Boyds, MD); Jingping Yang (Gaithersburg, MD); Cheng Cheng (Rockville, MD)
Assignee: Novartis AG
C12N7/00C12N2770/32032C12N2770/32061C12N2770/32022C12N2770/32021A61K2039/525A61K35/768A61K39/00C07K14/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,753,622
App. No.
13/209,124
Granted
Jun 17, 2014
Kind
B2
Abstract

The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.

Claims (5)

1. A method of killing an abnormally proliferative cell comprising contacting the cell with an isolated Seneca Valley virus or derivative or relative thereof, having a genome comprising a sequence that is at least 95% identical to SEQ ID NO:168, and wherein the abnormally proliferative cell is a neuroendocrine tumor cell.

2. The method of claim 1 , wherein the isolated Seneca Valley virus is the virus having ATCC Patent Deposit number PTA-5343.

3. The method of claim 1 , wherein the neuroendocrine tumor cell is a human neuroendocrine tumor cell.

4. The method of claim 3 , wherein the human neuroendocrine tumor cell is selected from the group consisting of: a small cell lung cancer (SCLC) cell, a large cell neuroendocrine carcinoma cell, a neuroblastoma, a Wilms' tumor cell, a retinoblastoma, a medulloblastoma, a non-SCLC tumor cell, a carcinoid tumor cell, and an adrenocortical carcinoma cell.

5. The method of claim 1 , wherein the isolated Seneca Valley virus is the virus having ATCC Patent Deposit number PTA-5343, and wherein the abnormally proliferative cell is a human neuroendocrine tumor cell selected from the group consisting of: a small cell lung cancer (SCLC) cell, a large cell neuroendocrine carcinoma cell, a neuroblastoma, a Wilms' tumor cell, a retinoblastoma, a medulloblastoma, a non-SCLC tumor cell, a carcinoid tumor cell, and an adrenocortical carcinoma cell.

Assignments (3)
CORRECTION BY DECLARATION FOR ERRONEOUSLY FILED U.S. PATENT NOS. 8,753,622, 7,638,318 AND 8,039,606 PER REEL: 036258; FRAME 0135 Recorded Apr 25, 2019
From: NOVARTIS AG
To: NOVARTIS AG
Reel/Frame 050315/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2015
From: NEOTROPIX INC
To: PERCEIVER PHARMACEUTICALS, LLC
Reel/Frame 036258/0135 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2014
From: HALLENBECK, PAUL L; POLICE, SESHIDAR REDDY; HALES, LAURA M; HAY, CARL M; GANESH, SHANTHI; XU, LING; YANG, JINGPING; CHENG, CHENG
To: NOVARTIS AG
Reel/Frame 032441/0161 →
Continuity (7)
Continuation 12576296 · Oct 9, 2009
Continuation 11335891 · Jan 19, 2006
Continuation In Part PCTUS2004031504 · Sep 23, 2004
Provisional Application 60726313 · Oct 13, 2005
Provisional Application 60664442 · Mar 23, 2005
Provisional Application 60506182 · Sep 26, 2003
Related Publication 20120034676A1 · Feb 9, 2012